infohep
  • Menu
  • Search
  • Home
  • News
  • About hepatitis
  • Countries
  • About us
  • Twitter
  • Facebook
  • RSS
  • Home
  • News
  • All the news

All the news

Showing 10 of 217 articles from: Pharmaceutical industry

Get an RSS feed of these articles

  • All news
  • infohep news
  • Editors' picks from other sources
  • Gilead rocked by phase 3 failure of selonsertib in NASH

    Fierce BioTech / 13 February 2019

  • Washington takes 'Netflix' hep C drug pricing further with winner-take-all bidding

    Fierce Pharma / 29 January 2019

  • The Economics Of Cures - Gilead At A Turning Point

    Seeking Alpha / 28 January 2019

  • UK court dismisses AbbVie's legal challenge against the NHS

    The Lancet (free registration required) / 25 January 2019

  • A Big, Fatty Opportunity for Big Pharma

    Wall Street Journal / 18 January 2019

  • NHS England’s plan to eliminate Hepatitis C decisively backed by High Court

    NHS England / 18 January 2019

  • Merck loses bid to revive $200 million Gilead verdict at U.S. high court

    Reuters UK / 08 January 2019

  • Mavyret maker AbbVie slaps NHS England with lawsuit over hepatitis C drug procurement: report

    FiercePharma / 11 November 2018

  • Gilead's HIV portfolio soars, but is it enough to combat falling HCV sales?

    FiercePharma / 29 October 2018

  • Janssen Announces Exclusive, Worldwide License Agreement With Arrowhead Pharmaceuticals to Develop and Commercialize a New Treatment for Chronic Hepatitis B Viral Infection

    Janssen press release / 05 October 2018

← Prev12345...22Next →
Other pages in this section
  • Latest news
  • All the news
    • Hepatitis A
    • Hepatitis B
    • Hepatitis C
    • Hepatitis D
    • Hepatitis E
    • Coronavirus
    • NAFLD
    • Treatment for hepatocellular carcinoma
    • Transmission, epidemiology and prevention
    • Health services, policy and advocacy
      • Access to medicines & diagnostics
      • Hepatitis C elimination
      • Models of care
      • Finance, funding & health economics
      • National policy
      • European policy
      • International policy
      • Activism and civil society
      • Pharmaceutical industry
    • Social issues
  • Conference news
  • Noticeboard
  • Email bulletins
  • News feeds

  • Contact us
  • Terms and conditions
  • Accessibility
  • Privacy and cookies

Latest hepatitis news

Sign-up for our monthly email bulletin Follow us on Twitter Find us on Facebook

The information on this website is intended to support, rather than replace, consultation with a healthcare professional.

©NAM Publications 2022. All rights reserved. We are not responsible for the content of external websites.

Company limited by guarantee. Registered in England & Wales, number: 2707596. Registered charity, number: 1011220

Infohep has been supported by a grant from Gilead Sciences Europe Ltd. Our funder has had no editorial control over the site’s content.

infohep

Latest treatment news and information for patient advocates and people working in hepatitis in Europe.

infohep is produced by NAM. Find out more about NAM

www.infohep.org/page//about-us/Find-out-about-NAM/page/2626330//